{
    "ticker": "PRLH",
    "name": "ProLung, Inc.",
    "description": "ProLung, Inc. is a healthcare technology company focused on improving the early detection of lung cancer through advanced diagnostic solutions. Founded in 2006, ProLung has developed an innovative, proprietary test that utilizes a non-invasive approach to assess lung cancer risk by measuring the electrical impedance of lung tissue. This groundbreaking technology aims to provide physicians with valuable information that can lead to earlier diagnosis and treatment of lung cancer, ultimately improving patient outcomes. ProLung's mission is to enhance the lives of patients by offering a reliable, cost-effective solution that addresses a critical need in lung cancer diagnostics. With a commitment to research and development, ProLung continues to explore new applications of its technology, aiming to expand its impact in the oncology field. The company is dedicated to collaborating with healthcare providers and partners to optimize lung cancer detection and treatment pathways, striving towards a future where lung cancer is detected earlier and treated more effectively.",
    "industry": [
        "Healthcare",
        "Medical Devices"
    ],
    "headquarters": "Salt Lake City, Utah, USA",
    "founded": "2006",
    "website": "https://www.prolung.com",
    "ceo": "Mark H. McClure",
    "social_media": {
        "twitter": "https://twitter.com/ProLungInc",
        "linkedin": "https://www.linkedin.com/company/prolung-inc/"
    },
    "investor_relations": "https://www.prolung.com/investors",
    "key_executives": [
        {
            "name": "Mark H. McClure",
            "position": "CEO"
        },
        {
            "name": "David H. Wiggins",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Tests",
            "products": [
                "ProLung Test"
            ]
        }
    ],
    "seo": {
        "meta_title": "ProLung, Inc. | Advanced Lung Cancer Diagnostics",
        "meta_description": "Learn about ProLung, Inc., a leader in innovative lung cancer diagnostic technology. Explore the ProLung Test and its impact on early lung cancer detection.",
        "keywords": [
            "ProLung",
            "Lung Cancer",
            "Diagnostic Technology",
            "Healthcare",
            "Medical Devices"
        ]
    },
    "faq": [
        {
            "question": "What does ProLung specialize in?",
            "answer": "ProLung specializes in lung cancer diagnostics through innovative testing technology."
        },
        {
            "question": "Who is the CEO of ProLung?",
            "answer": "Mark H. McClure is the CEO of ProLung, Inc."
        },
        {
            "question": "Where is ProLung headquartered?",
            "answer": "ProLung is headquartered in Salt Lake City, Utah, USA."
        },
        {
            "question": "What is the ProLung Test?",
            "answer": "The ProLung Test is a non-invasive diagnostic test that assesses lung cancer risk."
        },
        {
            "question": "When was ProLung founded?",
            "answer": "ProLung was founded in 2006."
        }
    ],
    "competitors": [
        "EXAS",
        "GHDX",
        "MDGL"
    ],
    "related_stocks": [
        "AAPL",
        "JNJ",
        "PFE",
        "MRK"
    ]
}